Carma Fund is an early-stage venture capital firm investing in life science and healthcare technologies across Europe. The fund, started in June 2022, focuses on the translation of therapeutics, diagnostics, medtech, and digital health assets.
33% of their portfolio is in Healthcare. Deal activity decreased year-over-year (2 deals in the last 12 months vs 5 prior). Their most common stage is seed (50% of deals). Average disclosed round size is $32.5M (across 3 rounds with reported amounts).
Portfolio
16
Fund Size
$61M
Top Stage
Seed
Last 12 Mo
2
Team
CL
Christian Leikert
Managing Partner
MR
Martin Raditsch
General Partner
TH
Thomas Hanke
Venture Partner
MM
Martin Müller
Venture Capital
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
18 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Exciva Gmbh | Series B | — | Jan 2026 |
| WWMT AG | Unknown | — | Oct 2025 |
 Elkedonia | Seed | — | Jun 2025 |
| Exciva Gmbh | Series B | $59M | Jan 2025 |
| AAkribion Therapeutics | Seed | — | Jan 2025 |
 Akribion | Seed | — | Jan 2025 |
 Aignostics | Series B | $34M | Oct 2024 |
 Symphera | Seed | — | Sep 2024 |
 Thryve | Series A | — | Sep 2024 |
 Epignostix | Seed | — | Jul 2024 |
 ACORAI AB | Seed | $4.5M | Jan 2024 |
 Thryve | Series A | — | Jan 2024 |
 Allogenetics | Seed | — | Jan 2024 |
 inContAlert | Pre-Seed | — | Sep 2023 |
| OO11 Biomedical | Seed | — | Jun 2023 |
| KKUPANDO | Series A | — | Sep 2022 |
| Aignostics | Series A | — | Sep 2022 |
 TECregen | Seed | — | — |
Top Co-Investors
High-Tech Gründerfonds10 shared
EQT Life Sciences3 shared
Andera Partners2 shared
LBBW VC2 shared
Fountain Healthcare Partners2 shared
LBBW Venture Capital2 shared
Mosaic Ventures2 shared
Gimv2 shared
LifeArc Ventures2 shared
Wellington Management2 shared
Bayern Kapital2 shared
Capricorn2 shared
IBB Ventures2 shared
Mayo Clinic1 shared
ATHOS1 shared
Athos Capital1 shared
Mayo Clinic Ventures1 shared
Bpifrance1 shared
Last updated: 27 September 2026